Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer.
<h4>Background</h4>Ampulla of Vater cancer (AoV Ca) is a rare tumor, and its adjuvant treatment has not been established. The purpose of this study was to find out prognostic factors including host immunity and role of adjuvant treatment in AoV Ca.<h4>Methods and findings</h4>...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0151406&type=printable |
| _version_ | 1826584122621952000 |
|---|---|
| author | Hye Rim Ha Do-Youn Oh Tae-Yong Kim KyoungBun Lee Kyubo Kim Kyung-Hun Lee Sae-Won Han Eui Kyu Chie Jin-Young Jang Seock-Ah Im Tae-You Kim Sun-Whe Kim Yung-Jue Bang |
| author_facet | Hye Rim Ha Do-Youn Oh Tae-Yong Kim KyoungBun Lee Kyubo Kim Kyung-Hun Lee Sae-Won Han Eui Kyu Chie Jin-Young Jang Seock-Ah Im Tae-You Kim Sun-Whe Kim Yung-Jue Bang |
| author_sort | Hye Rim Ha |
| collection | DOAJ |
| description | <h4>Background</h4>Ampulla of Vater cancer (AoV Ca) is a rare tumor, and its adjuvant treatment has not been established. The purpose of this study was to find out prognostic factors including host immunity and role of adjuvant treatment in AoV Ca.<h4>Methods and findings</h4>We reviewed 227 AoV Ca patients with curative resection. Clinical characteristics, adjuvant treatment, disease-free survival (DFS) and overall survival (OS) were analyzed. Among all patients, 63.9, 36.1 and 33.9% had T1/T2, T3/T4 stage and lymph node-positive disease (LN+), respectively. OS of all patients was 90.9 months (95% CI: 52.9-129.0). OS was different according to neutrophil-to-lymphocyte ratio (HR 1.651, 95% CI: 1.11-2.47), platelet-to-lymphocyte ratio (HR 1.488, 95% CI: 1.00-2.21) and systemic inflammatory index (HR 1.669, 95% CI: 1.13-2.47). In multivariate analysis, adverse prognostic factors for OS included vascular invasion (HR 2.571, 95% CI: 1.20-5.53) and elevated CA 19-9 (HR 1.794, 95% CI: 1.07-3.05). A total of 104 patients (46.3%) received adjuvant treatment (25 out of 111of T1/T2 & LN (-), 79 out of 116 of T3/T4 or LN (+)). In T3/T4 or LN (+) stage, adjuvant CCRT with maintenance chemotherapy provided the longest OS (5-year OS rate: 47.0 vs. 41.4%).<h4>Conclusions</h4>Vascular invasion and elevated CA 19-9 were adverse prognostic factors in resected AoV Ca. In T3/T4 or LN (+) stage, adjuvant CCRT with maintenance chemotherapy provided the best survival outcome. Adjuvant treatment should be further defined in AoV Ca, especially with poor prognostic factors. |
| first_indexed | 2024-12-22T09:35:33Z |
| format | Article |
| id | doaj.art-5a7a0e3a480b4665a5e5d9098fbca344 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2025-03-14T15:32:44Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-5a7a0e3a480b4665a5e5d9098fbca3442025-02-25T05:34:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01113e015140610.1371/journal.pone.0151406Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer.Hye Rim HaDo-Youn OhTae-Yong KimKyoungBun LeeKyubo KimKyung-Hun LeeSae-Won HanEui Kyu ChieJin-Young JangSeock-Ah ImTae-You KimSun-Whe KimYung-Jue Bang<h4>Background</h4>Ampulla of Vater cancer (AoV Ca) is a rare tumor, and its adjuvant treatment has not been established. The purpose of this study was to find out prognostic factors including host immunity and role of adjuvant treatment in AoV Ca.<h4>Methods and findings</h4>We reviewed 227 AoV Ca patients with curative resection. Clinical characteristics, adjuvant treatment, disease-free survival (DFS) and overall survival (OS) were analyzed. Among all patients, 63.9, 36.1 and 33.9% had T1/T2, T3/T4 stage and lymph node-positive disease (LN+), respectively. OS of all patients was 90.9 months (95% CI: 52.9-129.0). OS was different according to neutrophil-to-lymphocyte ratio (HR 1.651, 95% CI: 1.11-2.47), platelet-to-lymphocyte ratio (HR 1.488, 95% CI: 1.00-2.21) and systemic inflammatory index (HR 1.669, 95% CI: 1.13-2.47). In multivariate analysis, adverse prognostic factors for OS included vascular invasion (HR 2.571, 95% CI: 1.20-5.53) and elevated CA 19-9 (HR 1.794, 95% CI: 1.07-3.05). A total of 104 patients (46.3%) received adjuvant treatment (25 out of 111of T1/T2 & LN (-), 79 out of 116 of T3/T4 or LN (+)). In T3/T4 or LN (+) stage, adjuvant CCRT with maintenance chemotherapy provided the longest OS (5-year OS rate: 47.0 vs. 41.4%).<h4>Conclusions</h4>Vascular invasion and elevated CA 19-9 were adverse prognostic factors in resected AoV Ca. In T3/T4 or LN (+) stage, adjuvant CCRT with maintenance chemotherapy provided the best survival outcome. Adjuvant treatment should be further defined in AoV Ca, especially with poor prognostic factors.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0151406&type=printable |
| spellingShingle | Hye Rim Ha Do-Youn Oh Tae-Yong Kim KyoungBun Lee Kyubo Kim Kyung-Hun Lee Sae-Won Han Eui Kyu Chie Jin-Young Jang Seock-Ah Im Tae-You Kim Sun-Whe Kim Yung-Jue Bang Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. PLoS ONE |
| title | Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. |
| title_full | Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. |
| title_fullStr | Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. |
| title_full_unstemmed | Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. |
| title_short | Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. |
| title_sort | survival outcomes according to adjuvant treatment and prognostic factors including host immune markers in patients with curatively resected ampulla of vater cancer |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0151406&type=printable |
| work_keys_str_mv | AT hyerimha survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer AT doyounoh survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer AT taeyongkim survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer AT kyoungbunlee survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer AT kyubokim survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer AT kyunghunlee survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer AT saewonhan survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer AT euikyuchie survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer AT jinyoungjang survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer AT seockahim survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer AT taeyoukim survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer AT sunwhekim survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer AT yungjuebang survivaloutcomesaccordingtoadjuvanttreatmentandprognosticfactorsincludinghostimmunemarkersinpatientswithcurativelyresectedampullaofvatercancer |